Minapharm Pharmaceuticals S.A.E. specializes in developing, manufacturing and marketing prescription pharmaceutical products. The products are for the treatment of gastroenterological, ophthalmologic, cardiovascular, genetic, dermatological, orthopedic diseases, etc.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
28/26/28	EGP 643.50	+0.30%	2,053
25/26/25	EGP 641.55	-3.24%	3,090
24/26/24	EGP 663.03	+0.36%	2,336
23/26/23	EGP 660.66	-4.02%	4,534
22/26/22	EGP 688.30	-0.82%	1,108

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Egyptian Exchange Other stock markets 28/06/2026			5-day change	1st Jan Change
643.50 ^EGP	+0.30%		-7.28%	+84.28%

10/06	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05/05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE

Market Cap	758.1Cr 15Cr 13Cr 12Cr 12Cr 22Cr 1.44TCr 22Cr 148.75Cr 58Cr 713.93Cr 58Cr 56Cr 2.48TCr	P/E 2024	14x	P/E 2025	584x
Enterprise Value	869.11Cr 18Cr 15Cr 14Cr 13Cr 25Cr 1.66TCr 25Cr 170.54Cr 66Cr 818.47Cr 66Cr 64Cr 2.84TCr	EV / Sales 2024	0.78x	EV / Sales 2025	0.81x
Free-Float	14.74%	Yield 2024	1.54%	Yield 2025	-

10/06	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05/05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE
30/11	Minapharm Pharmaceuticals Q3 consol profit egp 16.8 million	RE
30/11	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/25/14	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
14/25/14	Minapharm Pharmaceuticals Q2 consol profit EGP 40 million	RE
27/25/27	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
27/25/27	Minapharm Pharmaceuticals Q1 consol net loss EGP 2 million	RE
12/25/12	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2024	CI
12/25/12	Minapharm Pharmaceuticals FY Colsol Net Profit EGP 161.1 Million	RE
26/25/26	Minapharm Pharmaceuticals FY Standalone Profit EGP 162.8 Million	RE
03/24/03	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
01/24/01	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

07/25/07	EBRD, Admaius Capital plan to acquire 15%-20% of Egyptian Minapharm Pharmaceuticals	AQ
26/25/26	African Development Bank Approves Eur 15 Million Loan to Boost Biosimilars' Development and Production in Egypt	AQ
05/23/05	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	AQ
05/23/05	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	AQ
06/23/06	Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	AQ

MINAPHARM Pharmaceuticals Share Price

Stocks

MIPH

EGS380G1C011

Pharmaceuticals

Valuation: MINAPHARM Pharmaceuticals

Chart: MINAPHARM Pharmaceuticals

Latest news : MINAPHARM Pharmaceuticals

Press Releases: MINAPHARM Pharmaceuticals

Quotes and Performance

Course Extremes

Managers and Directors: MINAPHARM Pharmaceuticals

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+0.30%
1 week	-7.28%
Current month	-1.27%
1 month	-1.27%
3 months	+39.89%
6 months	+81.89%
Current year	+84.28%

1 week	630.13	696
1 month	630.13	710
Current year	320.23	772
1 year	214.7	772
3 years	145	772
5 years	95.03	772
10 years	45	772

Manager	Title	Age	Since
Shaheer Wafeeq Sa'ad Al-Bardissy CEO	Chief Executive Officer	-	-
Wafik El-Bardissy CEO	Chief Executive Officer	-	19/10/2010
Rafiq Raymond DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Amr Mohamed Sobhi Hamza El-Shabrawishy BRD	Director/Board Member	-	-
Wafik El-Bardissy CHM	Chairman	-	18/10/2010
Anwar Nasr Mekhaeel BRD	Director/Board Member	-	18/10/2010

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MINAPHARM PHARMACEUTICALS	+0.30%	-7.28%	+175.97%	+192.51%	15Cr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+1.56%	+1.54%	+12.88%	+79.88%	4.74TCr
OTSUKA HOLDINGS CO., LTD.	+0.37%	+2.45%	+52.01%	+105.64%	3.55TCr
CIPLA LIMITED	+3.29%	+5.04%	-1.25%	+46.52%	1.23TCr
ZYDUS LIFESCIENCES LIMITED	+1.61%	+3.13%	+13.09%	+92.01%	1.16TCr
KRKA, D. D.	-0.76%	+0.38%	+36.72%	+126.29%	888.1Cr
GEDEON RICHTER	+0.99%	+4.52%	+21.27%	+44.41%	720.73Cr
ONO PHARMACEUTICAL CO., LTD.	+1.30%	+2.60%	+54.36%	-8.64%	691.07Cr
GLENMARK PHARMACEUTICALS LIMITED	+1.82%	+0.14%	+25.16%	+224.70%	644.5Cr
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-3.83%	-0.76%	-35.52%	-3.58%	494.11Cr
Average	+0.67%	+1.71%	+35.47%	+89.97%	1.41TCr
Weighted average by Cap.	+1.06%	+2.85%	+24.48%	+85.02%

	2024	2025
Net sales	566.48Cr 11Cr 10Cr 9.25Cr 8.66Cr 16Cr 1.08TCr 17Cr 111.15Cr 43Cr 533.47Cr 43Cr 42Cr 1.85TCr	643.82Cr 13Cr 11Cr 11Cr 9.84Cr 18Cr 1.23TCr 19Cr 126.33Cr 49Cr 606.3Cr 49Cr 48Cr 2.1TCr
Net income	16Cr 31.73L 27.82L 25.64L 24.01L 45.01L 30Cr 45.95L 3.08Cr 1.19Cr 15Cr 1.19Cr 1.17Cr 51Cr	4.02Cr 8L 7L 7L 6L 11.53L 7.66Cr 11.77L 78.91L 30.53L 3.79Cr 30.5L 29.84L 13Cr
Net Debt	259.82Cr 5.25Cr 4.6Cr 4.24Cr 3.97Cr 7.45Cr 495.07Cr 7.6Cr 51Cr 20Cr 244.68Cr 20Cr 19Cr 848.43Cr	111.01Cr 2.24Cr 1.97Cr 1.81Cr 1.7Cr 3.18Cr 211.53Cr 3.25Cr 22Cr 8.43Cr 104.54Cr 8.42Cr 8.24Cr 362.51Cr